Get the Stockscreener App
1.07
0.93%
-0.01
After Hours:
1.08
0.01
+0.93%
Lexicon Pharmaceuticals Inc stock is traded at $1.07, with a volume of 1.52M.
It is down -0.93% in the last 24 hours and down -4.46% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$1.08
Open:
$1.08
24h Volume:
1.52M
Relative Volume:
0.43
Market Cap:
$388.84M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.3375
EPS:
-0.8
Net Cash Flow:
$-162.37M
1W Performance:
-6.96%
1M Performance:
-4.46%
6M Performance:
+229.43%
1Y Performance:
-34.36%
1-Day Range:
$1.03
$1.09
1-Week Range:
$1.03
$1.20
52-Week Range:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.07 | 407.01M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Novel Pain Treatment Breakthrough: Lexicon's Pilavapadin Shows Promise for MS and Chemo Patients - Stock Titan
Combining price and volume data for Lexicon Pharmaceuticals Inc.Exit Point & Risk Controlled Swing Alerts - Newser
What is Lexicon Pharmaceuticals Inc.’s book value per shareJuly 2025 Review & Expert Verified Stock Movement Alerts - khodrobank.com
Can trapped investors hope for a rebound in Lexicon Pharmaceuticals Inc.July 2025 WrapUp & Verified Chart Pattern Trade Signals - Newser
Analyzing net buyer seller activity in Lexicon Pharmaceuticals Inc.Quarterly Trade Report & Daily Market Momentum Tracking - Newser
Lexicon Pharmaceuticals Inc. stock momentum explainedCPI Data & Daily Profit Maximizing Tips - Newser
Lexicon Pharmaceuticals' Strategic R&D Pivots and Licensing Catalysts in 2025 - AInvest
Lexicon Pharmaceuticals' Strategic Positioning in the Biopharma Sector - AInvest
Can Lexicon Pharmaceuticals Inc. generate free cash flow2025 Valuation Update & Weekly High Conviction Ideas - khodrobank.com
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 - The Manila Times
Lexicon Pharmaceuticals to Present Patient Insights on Diabetic Peripheral Neuropathic Pain at PAINWeek 2025 - Quiver Quantitative
30% of Diabetics Suffer Neuropathic Pain: Lexicon Study Reveals Impact on Daily Life at PAINWeek - Stock Titan
H.C. Wainwright reiterates Buy rating on Lexicon Pharmaceuticals stock at $4 - Investing.com
How to use a screener to detect Lexicon Pharmaceuticals Inc. breakouts2025 Performance Recap & High Accuracy Trade Alerts - Newser
Using Python tools to backtest Lexicon Pharmaceuticals Inc. strategiesEarnings Beat & Risk Controlled Swing Trade Alerts - Newser
Pattern recognition hints at Lexicon Pharmaceuticals Inc. upsideMarket Sentiment Report & Real-Time Chart Pattern Alerts - Newser
Update Recap: Can Lexicon Pharmaceuticals Inc. reach all time highs this year2025 Valuation Update & Real-Time Market Trend Scan - khodrobank.com
How to build a dashboard for Lexicon Pharmaceuticals Inc. stockMarket Trend Report & AI Optimized Trading Strategy Guides - Newser
Buybacks Report: What’s the MACD signal for Lexicon Pharmaceuticals Inc.Market Volume Summary & Technical Entry and Exit Alerts - khodrobank.com
Price action breakdown for Lexicon Pharmaceuticals Inc.Market Movement Recap & High Accuracy Swing Entry Alerts - Newser
Is Lexicon Pharmaceuticals Inc. meeting your algorithmic filter criteriaLong Setup & Safe Capital Growth Stock Tips - Newser
28% Heart Failure Risk Reduction: Lexicon's Sotagliflozin Proves Equally Effective in Elderly Patients Over 75 - Stock Titan
Ideas Watch: Is Lexicon Pharmaceuticals Inc. benefiting from innovation trendsJuly 2025 Market Mood & Community Trade Idea Sharing Platform - khodrobank.com
What is Lexicon Pharmaceuticals Inc.’s valuation compared to sectorPortfolio Return Summary & Safe Capital Growth Trade Ideas - khodrobank.com
Can Lexicon Pharmaceuticals Inc. ride the EV waveRate Cut & Daily Entry Point Alerts - khodrobank.com
What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)July 2025 Intraday Action & Real-Time Volume Trigger Notifications - khodrobank.com
Analysts Backtest Strategies on Lexicon Pharmaceuticals Inc. With Promising Results getLinesFromResByArray error: size == 0 - kangso.co.kr
What’s the RSI of Lexicon Pharmaceuticals Inc. stockQuarterly Profit Report & Real-Time Buy Zone Alerts - khodrobank.com
MACD Cross Could Confirm Trend in Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & Target Return Focused Stock Picks - beatles.ru
Visual analytics tools that track Lexicon Pharmaceuticals Inc. performanceMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Measuring Lexicon Pharmaceuticals Inc.’s beta against major indices2025 Buyback Activity & Reliable Momentum Entry Alerts - Newser
Should you hold or exit Lexicon Pharmaceuticals Inc. nowJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - Newser
Heatmap analysis for Lexicon Pharmaceuticals Inc. and competitors2025 Market WrapUp & Weekly High Return Stock Forecasts - Newser
Can momentum traders help lift Lexicon Pharmaceuticals Inc.July 2025 Recap & Expert Curated Trade Ideas - Newser
Strategies to average down on Lexicon Pharmaceuticals Inc.July 2025 Retail & Weekly High Return Opportunities - Newser
Will Lexicon Pharmaceuticals Inc. outperform tech stocksJuly 2025 Summary & Stepwise Trade Signal Guides - sundaytimes.kr
Real time alert setup for Lexicon Pharmaceuticals Inc. performanceIndex Update & Reliable Price Breakout Alerts - Newser
Will Lexicon Pharmaceuticals Inc. face regulatory challenges2025 Short Interest & Step-by-Step Swing Trade Plans - 한국정경신문
Top chart patterns to watch in Lexicon Pharmaceuticals Inc.July 2025 EndofMonth & Weekly Momentum Stock Picks - Newser
Exit strategy if you’re trapped in Lexicon Pharmaceuticals Inc.Trade Risk Report & Growth Oriented Trade Recommendations - Newser
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lexicon Pharmaceuticals Inc Stock (LXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):